We are live on ! Find out more
CBMG

Cellular Biomedicine Group, Inc.
CBMG

Delisted

CBMG was delisted on the 19th of February, 2021.

Back to rankings

6 hedge funds and large institutions have $416K invested in Cellular Biomedicine Group, Inc. in 2014 Q4 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

14% less funds holding

Funds holding: 7 → 6 (-1)

20% less capital invested

Capital invested by funds: $522K → $416K (-$106K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
6
Holders Change
-1
Holders Change %
-14.29%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$261K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$126K
2
Morgan Stanley
Morgan Stanley
New York
-$47.9K
3
Bank of America
Bank of America
North Carolina
-$11K
4
TRCT
Tower Research Capital (TRC)
New York
-$4K

CBMG Hedge Fund Activity: Q4 2014 in Review

6 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Cellular Biomedicine Group, Inc. (CBMG) for Q4 2014, worth a combined $416K — down 20% from $522K a quarter earlier.

Fund positioning in CBMG was balanced in Q4 2014: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 2 trimmed.

The largest buyer was Geode Capital Management, opening a new position worth an estimated $261K. The largest seller was Goldman Sachs, cutting an estimated $126K.

  • 6 institutional investors held Cellular Biomedicine Group, Inc. (CBMG) as of Q4 2014, down from 7 in Q3 2014.
  • Funds reported $416K of Cellular Biomedicine Group, Inc. stock for Q4 2014, down 20% quarter-over-quarter.
  • 2 funds opened new Cellular Biomedicine Group, Inc. positions in Q4 2014 and 2 closed out, a net change of 0 holders.
  • The largest Cellular Biomedicine Group, Inc. buyer in Q4 2014 was Geode Capital Management, an estimated $261K added.
  • The largest Cellular Biomedicine Group, Inc. seller in Q4 2014 was Goldman Sachs, an estimated $126K sold.

Based on aggregated 13F filings for Q4 2014.